Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation

Acute Myeloid Leukemia (AML) Clinical Trial

— ILDA  

Official title:

Phase I Study Testing the Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04886206
• Other study ID #: RC20_0357
• Status: Recruiting
• Phase: Phase 1
• Start date: November 10, 2021
• Est. completion date: November 2024

Study information

• Verified date: May 2022
• Source: Nantes University Hospital
• Contact: Thierry Guillaume
• Phone: 02 40 08 49 45
• Email: thierry.guillaume[@]chu-nantes.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with high risk AML non eligible for an intensive treatment and for an allogeneic transplantation will be treated with azacitidine and venetoclax. The fourth, fifth and sixth injection of azacitidine will be followed by injection of haplo-identical lymphocytes (HLI). This is a single-center phase I study to identify the dose of HLI with the most tolerable toxicity. TheBayesian continuous reassessment method (CRM) will be used

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: November 2024
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age =18 years
• patients with de novo or secondary AML, with an unfavorable or intermediate karyotype (according to the 2017 ELN classification), or patients with relapsing AML who may receive second-line treatment
• not candidates for intensive induction, for the following reasons
• 75 years or = 18 to 74 years and at least one of the following comorbidities: PS = 2 or a history of heart failure requiring treatment or LVEF = 50% or chronic stable angina or FEV1 = 65% or DLCO = 65% or creatinine clearance <45 ml / min; or liver damage with total bilirubin> 1.5 N or other comorbidities that the hematologist considers incompatible with intensive treatment
• ineligible for a classic allogeneic hematopoietic stem cell transplant due to the presence of co-morbidities or too high a risk of toxicity >70 years old or at least one of the following comorbidities: PS = 2 or a history of heart failure requiring treatment or LVEF = 50% or chronic stable angina or FEV1 = 65% or DLCO = 65% or creatinine clearance <45 ml / min; or liver damage with total bilirubin> 1.5 N
• may receive chemotherapy with hypomethylating agents have a partially compatible (haplo-identical) major family donor (=18 years old) eligible for lymphocyte donation.

Exclusion Criteria:

• AML with favorable karyotype (according to ELN 2017) in RC1
• Patient with refractory or progressive AML
• Other progressive cancer in progress
• Karnosky index <60% or PS> 2
• Severe hepatic function disturbance: transaminases> 5 N, hyperbilirubinemia> 30 µm / L
• Severe infection requiring hospitalization.
• Psychiatric illness compromising the understanding of the information or the carrying out of the study.
• woman of childbearing potential and refusing an effective method of contraception.
• Minor
• Adult under tutorship or curatorship, under legal protection or under family authorization
• Minor family donor (<18 years old)

Related Conditions & MeSH terms

• Acute Myeloid Leukemia (AML)
• Leukemia
• Leukemia, Myeloid, Acute

Intervention

Biological:
• DLI
the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.

Locations

Country	Name	City	State
France	CHU de Nantes	Nantes

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of DLT		by day 14
Secondary	cumulative incidence of relapse		1 YEAR
Secondary	relapse-free survival		1 YEAR
Secondary	overall survival		1 YEAR